These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33463906)

  • 1. Designing and analyzing clinical trials for personalized medicine via Bayesian models.
    Zhang C; Mayo MS; Wick JA; Gajewski BJ
    Pharm Stat; 2021 May; 20(3):573-596. PubMed ID: 33463906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
    Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
    Trials; 2024 May; 25(1):312. PubMed ID: 38725072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian hierarchical modeling in interim futility analysis for two parallel clinical trials.
    Li H; Roy D; Deng Q
    Stat Med; 2024 Feb; 43(3):548-559. PubMed ID: 38038154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Bayesian early stopping boundaries for phase II clinical trials.
    Jiang L; Yan F; Thall PF; Huang X
    Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian basket trial design with exchangeability monitoring.
    Hobbs BP; Landin R
    Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variance prior specification for a basket trial design using Bayesian hierarchical modeling.
    Cunanan KM; Iasonos A; Shen R; Gönen M
    Clin Trials; 2019 Apr; 16(2):142-153. PubMed ID: 30526008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
    Johnston SE; Lipkovich I; Dmitrienko A; Zhao YD
    Pharm Stat; 2022 Sep; 21(5):1090-1108. PubMed ID: 35322520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
    Zhang J; Lin R; Chen X; Yan F
    Clin Trials; 2024 Jun; 21(3):308-321. PubMed ID: 38243401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
    Li W; Fu H
    J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.